Health Care • Biotechnology: Pharmaceutical Preparations
$143.45 ▼ -0.06
(-0.04%)
MKT CAP: $7.51B • VOL: 850.5K
52W L $124 52W H $260
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$121
MEDIAN
$161
MEAN
$164
HIGH
$195
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE AXSM TAPE
AXSM // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $173.57 | $164.97 | 2025-02-14 | $130.54 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $180.75 | $169.27 | 2025-02-06 | $134.84 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $163.53 | $157.79 | 2025-01-29 | $137.71 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $146.32 | — | 2025-01-17 | $140.58 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $126.24 | $136.28 | 2025-01-09 | $127.67 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $170.71 | $149.19 | 2024-12-18 | $124.80 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $139.15 | $144.88 | 2024-12-04 | $133.41 | -4.3% | 48% | C |